ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Must be legal age of consent
- Must have active rheumatoid arthritis based upon the American College of Rheumatology (ACR) 1987 (Revised Criteria); minimum disease criteria required for entry into the efficacy component of the study
- Must meet ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II, or III
- Must be receiving methotrexate for at least 12 weeks duration and on a stable dose for 4 weeks.
- Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory
arthritis that would interfere with disease activity assessments.
- Subject receiving prior treatment with certain medications for rheumatoid arthritis
- Tuberculosis and/or a positive tuberculin reaction
- Significant trauma or major surgery within 2 months
- History of alcohol and/or drug abuse outside of a defined period of abstinence
- History of or a finding at screening of postural hypotension
- Any condition that would affect the oral absorption of the drug
- History of cancer and in remission less than 3 years or Grade III-IV congestive heart
failure
- Having an infection of human immunodeficiency virus (HIV), Hepatitis B or C or
evidence of any active infection
- Abnormalities of clinical or laboratory assessments completed at the screening visit
such as elevated liver enzymes, decreased hemoglobin or an abnormal ECG
- Having a positive chemokine receptor 5 (CCR5) delta 32 mutation
- Requiring the use of certain medications
- Lactating or pregnant women or subjects have reproductive potential unwilling to use
an adequate method of birth control
- Chronic or recent serious or life-threatening infection; severe , progressive and/or
uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary,
cardiac, neurological disease within 12 weeks of the first dose.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Montpellier,
- Lille,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Maraviroc in Rheumatoid Arthritis | |||
| Official Title ICMJE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | |||
| Brief Summary | The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients. | |||
| Detailed Description | Following a planned interim analysis in the POC component on 21 August 2008 by the internal DMC (Data Monitoring Committee) of study A4001056, the trial was discontinued due to lack of efficacy. All participating investigators/country offices and monitors were notified on 22 August 2008 to cease patient enrollment. The DMC indicated that maraviroc was well tolerated in the Rheumatoid Arthritis patients and there were no safety concerns in the study. The termination date of this trial was 07 October 2008 when the last patient last visit occurred. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
| Condition ICMJE | Arthritis, Rheumatoid | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * | Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Terminated | |||
| Actual Enrollment ICMJE | 128 | |||
| Original Enrollment ICMJE | 130 | |||
| Actual Study Completion Date ICMJE | October 2008 | |||
| Actual Primary Completion Date | October 2008 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Australia, Germany, India, Italy, Mexico, Portugal, Spain, Ukraine, United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00427934 | |||
| Other Study ID Numbers ICMJE | A4001056 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | October 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||